Exclusive Summary

• Leading Stage & Novel Mechanism: UB565 is an EGFR/c-MET dual-targeting bispecific ADC with first-in-class potential, currently in Phase 1/2 clinical trials, positioning it within the global first tier of its targeted pipeline.
• Exceptional Efficacy Overcoming Resistance: Early clinical data shows a 44.4% ORR and 100% DCR in the ≥4 mg/kg dose cohort. Preclinically, it effectively targets osimertinib-sensitive, mutated-resistant, and low-expression tumors.
• Differentiated Safety Profile: Boasts a wider therapeutic window with no Dose-Limiting Toxicities (DLTs) up to 6.6mg/kg. Notably, no Interstitial Lung Disease (ILD) or ≥Grade 4 adverse events were observed, directly solving major toxicity issues in typical ADCs.
• High Readiness for License-out: Backed by a comprehensive global patent layout, highly aligning with MNCs' strategic needs for 'next-gen safe ADCs' that overcome 3rd-gen EGFR-TKI resistance, making it an excellent global License-out asset.

Asset Materials

Contact Us for Full Materials